Glaukos/$GKOS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Glaukos
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Ticker
$GKOS
Sector
Primary listing
NYSE
Employees
1,094
Headquarters
Website
Glaukos Metrics
BasicAdvanced
$8.2bn
-
-$3.29
0.78
-
Price and volume
Market cap
$8.2bn
Beta
0.78
52-week high
$146.75
52-week low
$73.16
Average daily volume
772k
Financial strength
Current ratio
5.433
Quick ratio
4.433
Long term debt to equity
15.36
Total debt to equity
15.36
Interest coverage (TTM)
-18.69%
Profitability
EBITDA (TTM)
-46.522
Gross margin (TTM)
78.08%
Net profit margin (TTM)
-34.34%
Operating margin (TTM)
-15.58%
Effective tax rate (TTM)
2.67%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
-5.78%
Return on equity (TTM)
-26.39%
Valuation
Price to revenue (TTM)
14.626
Price to book
12.02
Price to tangible book (TTM)
17.11
Growth
Revenue change (TTM)
36.30%
Earnings per share change (TTM)
45.12%
3-year revenue growth (CAGR)
24.01%
10-year revenue growth (CAGR)
21.27%
3-year earnings per share growth (CAGR)
4.06%
10-year earnings per share growth (CAGR)
8.79%
What the Analysts think about Glaukos
Analyst ratings (Buy, Hold, Sell) for Glaukos stock.
Glaukos Financial Performance
Revenues and expenses
Glaukos Earnings Performance
Company profitability
Glaukos News
AllArticlesVideos
Glaukos Announces the Release of its 2025 Sustainability Report
Business Wire·3 weeks ago
Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29
Business Wire·4 weeks ago
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Glaukos stock?
Glaukos (GKOS) has a market cap of $8.2B as of May 04, 2026.
What is the P/E ratio for Glaukos stock?
The price to earnings (P/E) ratio for Glaukos (GKOS) stock is 0 as of May 04, 2026.
Does Glaukos stock pay dividends?
No, Glaukos (GKOS) stock does not pay dividends to its shareholders as of May 04, 2026.
When is the next Glaukos dividend payment date?
Glaukos (GKOS) stock does not pay dividends to its shareholders.
What is the beta indicator for Glaukos?
Glaukos (GKOS) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.